ARS Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Donn Casale
- Full Time Employees
- 157
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11682 El Camino Real San Diego CA United States of America 92130
- IPO Date
- Dec 4, 2020
- CIK
- 0001671858
- Website
- ars-pharma.com
- Similar Companies
- Business
- ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for severe allergic reactions, including anaphylaxis. Its primary product offering is neffy®, the first and only FDA-approved needle-free intranasal epinephrine spray designed for the emergency treatment of Type I allergic reactions in adults and children aged 4 years and older who weigh 33 pounds or more. Neffy® combines epinephrine with an absorption enhancer to provide rapid, injection-like absorption in a small, easy-to-use nasal spray, aiming to improve patient and caregiver confidence and prompt administration of epinephrine upon symptom onset. The company also conducts ongoing clinical trials for expanding the use of its intranasal epinephrine technology into additional indications such as chronic spontaneous urticaria. ARS Pharmaceuticals operates primarily in the United States and Europe, with headquarters in San Diego, California. Founded prior to its public listing and presently traded under the ticker SPRY on NASDAQ, the company targets at-risk patients with severe allergies, healthcare providers, and caregivers, offering a patient-friendly alternative to traditional injectable epinephrine products. Recent significant developments for ARS Pharmaceuticals include a strategic licensing agreement with ALK-Abelló A/S, under which ARS received an upfront payment of $145 million and is eligible for up to $320 million in regulatory and commercial milestone payments plus tiered royalties. This partnership assigns ALK responsibility for marketing, local market access, and sales of the neffy® product. In 2025, ARS launched a national direct-to-consumer advertising campaign to increase product awareness, contributing to a 180% increase in weekly prescription volumes of neffy® in the U.S. Furthermore, the company initiated a Phase 2b clinical trial for the treatment of acute flares in chronic spontaneous urticaria, enrolling patients across the U.S. and Europe, with topline data expected in early 2026. ARS has also secured broad commercial payer coverage, achieving 93% commercial coverage in the U.S. including 57% without prior authorization, substantially reducing administrative barriers for providers. Overall, ARS Pharmaceuticals delivers comprehensive allergy treatment solutions through its flagship neffy® nasal spray, supported by robust clinical development programs, strong commercial partnerships, and expanding market access across North America and Europe. The company’s financial position and strategic initiatives position it for continued growth in the biopharmaceutical allergy treatment sector.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
Kaplan Fox Reminds ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery of the Lead Plaintiff Deadline on October 5, 2026
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY
The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY
ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript
ARS Pharmaceuticals Q2 Earnings Call Highlights
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY)
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (SPRY) Who Suffered Losses to Contact the Firm Before October 5, 2026
SPRY CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class Action - Contact the Firm
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit